Developer docs
API playgroundTry for free, no card

Search company profiles

Mapp Biopharmaceutical

Full company profile

uuid0002lls

Namestring
Mapp Biopharmaceutical
Legal namestring
Mapp Biopharmaceutical, Inc.
Websiteurl
mappbio.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Mapp Biopharmaceutical, Inc. is a privately held, founder-owned clinical-stage biopharmaceutical company founded in 2003 in San Diego, California by Drs. Kevin Whaley and Larry Zeitlin. The company develops monoclonal antibody therapeutics targeting high-consequence infectious diseases and biodefense threats, with a current pipeline spanning multiple ebolavirus species (MBP134, a broad-spectrum cocktail), Marburg virus (MBP091), Nipah virus, Botulinum Neurotoxin, Junin virus, ricin, and other priority pathogens. Its core technology platform uses affinity maturation to engineer antibodies with broadened neutralizing activity across viral species and strains, enabling coverage that single-target therapeutics cannot match.

Mapp's business model is government-countermeasure procurement-driven rather than commercial. Revenue flows primarily from U.S. federal contracts awarded by BARDA and ASPR for advanced development, Phase 1 clinical trials, and potential purchase of investigational therapeutics for the Strategic National Stockpile. Disclosed federal contract value exceeds $141 million across three awards (2018, 2019, 2022), with options bringing headline value to roughly $204 million. Products are investigational and provided through expanded access or WHO-coordinated clinical trials in outbreak settings; commercial pricing does not exist and the products, once procured, are owned by the U.S. government. Distribution occurs exclusively through government stockpiling, clinical-trial deployment, and emergency-use mechanisms, with no traditional pharmaceutical sales or marketing infrastructure.

The customer base is concentrated almost entirely within U.S. federal health and biodefense agencies (BARDA, ASPR, HHS), with operational reach extending into outbreak-affected geographies (DRC, India, Bangladesh) via partnerships with WHO, the University of Oxford, Vanderbilt University Medical Center, Albert Einstein College of Medicine, and Gilead Sciences. The company maintains a small employee base of 11-50 and has no institutional VC/PE investors, remaining fully owned by its two scientist founders. Its competitive position rests on proprietary antibody-engineering know-how, exclusive survivor-derived antibody licenses, deep federal-agency relationships, and the capital-intensive nature of BSL-3/4 countermeasure development that discourages larger commercial pharma participation.

Short descriptiontext

Mapp Biopharmaceutical is a San Diego-based, founder-owned clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for high-consequence infectious diseases (Ebola, Marburg, Nipah) and biodefense threats, funded primarily through U.S. federal BARDA and ASPR contracts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapeutics, infectious disease treatments, biodefense countermeasures, filovirus therapeutics, antiviral drug development
Industry2 codes
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Infectious Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Government Contracts and BARDA Funding
TypeLicensing Royalties
Description

Mapp Biopharmaceutical generates revenue primarily through government contracts with BARDA, ASPR, and other federal agencies. These contracts fund advanced development and procurement of medical countermeasures for biodefense and emerging infectious diseases. Contracts include advanced research and development funding, Phase 1 clinical trial support, and potential purchase agreements for successful therapeutics.

fiercebiotech.com
2U.S. Government Procurement
TypeOne Time License
Description

The U.S. government (Department of Health and Human Services, ASPR, BARDA) procures Mapp's investigational therapeutics for the Strategic National Stockpile and emergency response. Existing doses are owned by the U.S. government.

mappbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mapp Biopharmaceutical develops investigational monoclonal antibody therapeutics for the prevention and treatment of infectious diseases, with emphasis on filoviruses (Ebola, Marburg, Bundibugyo), Nipah virus, and other high-consequence pathogens as well as biodefense threats (botulinum neurotoxin, ricin). The company's products are advanced through Phase 1 clinical trials and procured primarily through U.S. government contracts with BARDA and ASPR, with deployment via the Strategic National Stockpile, WHO-coordinated outbreak clinical trials, and expanded access programs.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mapp Biopharmaceutical develops a portfolio of monoclonal antibody therapeutics for infectious diseases, focusing on unmet needs in global health and biodefense. The core products include MBP134 (broad-spectrum anti-filovirus cocktail targeting multiple Ebola species), MBP091 (pan-Marburg therapeutic), ZMapp (Ebola virus treatment), Nipah monoclonal antibody, Botulinum Neurotoxin therapeutic, and earlier-stage candidates for hantavirus, Crimean Congo Hemorrhagic Fever virus, and ricin. The company was founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin and maintains collaborations with BARDA, NIH, and academic partners.

Product and service7 records
1MBP134
CategoryAntiviral Therapeutics
Description

Investigational monoclonal antibody cocktail targeting multiple ebolaviruses including Zaire, Sudan, Bundibugyo, Reston, Tai Forest, and Bombali species; designed for broad-spectrum treatment of Ebola virus disease.

2MBP091
CategoryAntiviral Therapeutics
Description

Single human monoclonal antibody developed as a pan-Marburg virus therapeutic for treatment of hemorrhagic fevers caused by Marburg and closely related Ravn virus; isolated at Vanderbilt University Medical Center from a Marburg survivor.

3ZMapp
CategoryAntiviral Therapeutics
Description

Cocktail of mouse-human chimeric monoclonal antibodies for Ebola virus (Zaire ebolavirus); granted Orphan Medicinal Product Designation by EMA and Fast Track Status by FDA.

4Nipah Monoclonal Antibody
CategoryAntiviral Therapeutics
Description

Novel Nipah monoclonal antibody undergoing human clinical trials in India and Bangladesh; designed to offer immediate post-exposure protection against Nipah virus.

5Botulinum Neurotoxin Therapeutic
CategoryBiodefense Therapeutics
Description

Next-generation monoclonal antibody-based therapeutic for Botulinum Neurotoxin (BoNT) being developed in partnership with BARDA for biodefense preparedness.

6Ricin Antibody
CategoryBiodefense Therapeutics
Description

Monoclonal antibodies providing protection against ricin toxin, including plant-based expression of partially humanized neutralizing antibodies, for biodefense applications.

7Junin Virus Antibody
CategoryAntiviral Therapeutics
Description

Humanized monoclonal antibody therapeutic developed for Argentine hemorrhagic fever caused by Junin virus.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

University of Oxford is leading clinical trials of MBP134 and Gilead antivirals in the DRC Ebola outbreak, working with Congolese and Ugandan governments under WHO sponsorship. Oxford is also developing Bundibugyo vaccine candidates in collaboration with the Serum Institute of India.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

Gilead Sciences is donating doses of remdesivir and obeldesivir for WHO-sponsored clinical trials in DRC, testing Mapp's MBP134 alongside Gilead antivirals to evaluate individual and combination therapy approaches for Bundibugyo ebolavirus.

3The Alliance for International Medical Action (ALIMA)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

ALIMA is partnering with DRC's National Institute for Biomedical Research and Oxford University in WHO-sponsored clinical trials of Mapp and Gilead therapeutics against Bundibugyo ebolavirus.

fiercebiotech.com
4Democratic Republic of Congo National Institute for Biomedical Research
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

DRC's National Institute for Biomedical Research is collaborating with WHO, Oxford University, and ALIMA to conduct clinical trials of Mapp's MBP134 and Gilead's antivirals against the Bundibugyo ebolavirus outbreak.

fiercebiotech.com
5Vanderbilt University Medical Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-06-11
Description

Dr. James Crowe's laboratory at Vanderbilt isolated the MBP091 monoclonal antibody from a survivor of Marburg virus infection. The antibody was subsequently licensed by Mapp for development as a pan-Marburg therapeutic.

mappbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-09-28
Description

Collaboration with Adimab LLC led by Dr. Laura Walker for identification of monoclonal antibodies from survivors of the 2013-2016 Ebola outbreak. Mapp obtained exclusive license to develop and commercialize these antibodies from Adimab and Albert Einstein College of Medicine. The partnership utilized Adimab's antibody discovery platform.

7Albert Einstein College of Medicine
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-09-28
Description

Academic partner in the antibody discovery collaboration. Part of NIAID-supported Centers of Excellence for Translational Research at four institutions. Mapp obtained exclusive license to develop and commercialize antibodies from Adimab and Einstein.

mappbio.com
8National Institute of Allergy and Infectious Diseases (NIAID)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-09-28
Description

NIAID-supported Centers of Excellence for Translational Research at multiple institutions (Albert Einstein College of Medicine, Public Health Agency of Canada, University of Texas Medical Branch at Galveston, and USAMRIID) collaborated on antibody identification. NIAID funding supported research through grants (U19AI109711, U19AI109762, HHSN2722011000221).

mappbio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immunology company developing monoclonal antibody therapeutics for serious infectious diseases, including influenza, hepatitis B, and coronaviruses. Directly comparable to Mapp in antibody platform, infectious disease focus, and pre-commercial clinical development stage.

TypeBroad incumbent
Description

Large biotech with a deep monoclonal antibody platform that developed REGN-EB3 (Inmazeb), an approved Ebola therapeutic that directly competes with Mapp's ZMapp/MBP134 in the filovirus treatment market. Comparable antibody technology and government countermeasure positioning.

TypeDirect peer
Description

Commercial-stage biotech developing therapeutics for rare infectious diseases and hereditary angioedema. Comparable business model targeting underserved infectious disease indications with government stockpiling and small patient populations.

TypeBroad incumbent
Description

Specialty biopharmaceutical company focused on biodefense and public health preparedness products, including vaccines and antibody therapeutics for anthrax, smallpox, and botulinum. Comparable biodefense countermeasure business with strong U.S. government customer base.

TypeBroad incumbent
Description

Large antiviral pharmaceutical company and current Mapp partner donating remdesivir/obeldesivir for combination trials in the Bundibugyo outbreak. Overlapping infectious disease franchise and government countermeasure positioning.

TypeEmerging player
Description

Late-stage biopharmaceutical company developing therapeutics for infectious diseases, including the approved oral antiviral molnupiravir for COVID-19 and Ebola antibody programs. Comparable emerging infectious disease biotech with government-aligned business model.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing polyclonal antibody therapeutics for infectious diseases and immune disorders. Comparable antibody platform focus and government countermeasure contracts.

8Leaf Biopharmaceutical
TypeEmerging player
Description

Biopharmaceutical company that in-licensed Mapp's filovirus monoclonal antibody technology in 2014 for commercialization. Closely connected emerging player in the same therapeutic area.

TypeBroad incumbent
Description

Large pharmaceutical company with a major vaccines and infectious disease franchise, including Ervebo Ebola vaccine and partnerships with government health authorities on outbreak response. Comparable global infectious disease countermeasure footprint.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing mRNA-based vaccines and therapeutics for infectious diseases and oncology. Comparable emerging biotech with government countermeasure contracts and infectious disease focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mapp Biopharmaceutical

Infectious Disease Therapeuticsmappbio.com

Mapp Biopharmaceutical is a San Diego-based, founder-owned clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for high-consequence infectious diseases (Ebola, Marburg, Nipah) and biodefense threats, funded primarily through U.S. federal BARDA and ASPR contracts.

What Mapp Biopharmaceutical does

Mapp Biopharmaceutical, Inc. is a privately held, founder-owned clinical-stage biopharmaceutical company founded in 2003 in San Diego, California by Drs. Kevin Whaley and Larry Zeitlin. The company develops monoclonal antibody therapeutics targeting high-consequence infectious diseases and biodefense threats, with a current pipeline spanning multiple ebolavirus species (MBP134, a broad-spectrum cocktail), Marburg virus (MBP091), Nipah virus, Botulinum Neurotoxin, Junin virus, ricin, and other priority pathogens. Its core technology platform uses affinity maturation to engineer antibodies with broadened neutralizing activity across viral species and strains, enabling coverage that single-target therapeutics cannot match.

Mapp's business model is government-countermeasure procurement-driven rather than commercial. Revenue flows primarily from U.S. federal contracts awarded by BARDA and ASPR for advanced development, Phase 1 clinical trials, and potential purchase of investigational therapeutics for the Strategic National Stockpile. Disclosed federal contract value exceeds $141 million across three awards (2018, 2019, 2022), with options bringing headline value to roughly $204 million. Products are investigational and provided through expanded access or WHO-coordinated clinical trials in outbreak settings; commercial pricing does not exist and the products, once procured, are owned by the U.S. government. Distribution occurs exclusively through government stockpiling, clinical-trial deployment, and emergency-use mechanisms, with no traditional pharmaceutical sales or marketing infrastructure.

The customer base is concentrated almost entirely within U.S. federal health and biodefense agencies (BARDA, ASPR, HHS), with operational reach extending into outbreak-affected geographies (DRC, India, Bangladesh) via partnerships with WHO, the University of Oxford, Vanderbilt University Medical Center, Albert Einstein College of Medicine, and Gilead Sciences. The company maintains a small employee base of 11-50 and has no institutional VC/PE investors, remaining fully owned by its two scientist founders. Its competitive position rests on proprietary antibody-engineering know-how, exclusive survivor-derived antibody licenses, deep federal-agency relationships, and the capital-intensive nature of BSL-3/4 countermeasure development that discourages larger commercial pharma participation.

Mapp Biopharmaceutical firmographics

Firmographics
Name
Mapp Biopharmaceutical
Legal name
Mapp Biopharmaceutical, Inc.
Website
https://mappbio.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
51–100 employees
Short description
Mapp Biopharmaceutical is a San Diego-based, founder-owned clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for high-consequence infectious diseases (Ebola, Marburg, Nipah) and biodefense threats, funded primarily through U.S. federal BARDA and ASPR contracts.
Ownership category
akta.pro rank

Mapp Biopharmaceutical industry classification

Industry
Product category
Infectious Disease Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines

Keywords

  • Monoclonal antibody therapeutics
  • Infectious disease treatments
  • Biodefense countermeasures
  • Filovirus therapeutics
  • Antiviral drug development

Where Mapp Biopharmaceutical is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mapp Biopharmaceutical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure

Revenue model

  1. Government Contracts and BARDA Funding: Mapp Biopharmaceutical generates revenue primarily through government contracts with BARDA, ASPR, and other federal agencies. These contracts fund advanced development and procurement of medical countermeasures for biodefense and emerging infectious diseases. Contracts include advanced research and development funding, Phase 1 clinical trial support, and potential purchase agreements for successful therapeutics.
  2. U.S. Government Procurement: The U.S. government (Department of Health and Human Services, ASPR, BARDA) procures Mapp's investigational therapeutics for the Strategic National Stockpile and emergency response. Existing doses are owned by the U.S. government.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Mapp Biopharmaceutical product offering

Product offering

Core offering

Mapp Biopharmaceutical develops investigational monoclonal antibody therapeutics for the prevention and treatment of infectious diseases, with emphasis on filoviruses (Ebola, Marburg, Bundibugyo), Nipah virus, and other high-consequence pathogens as well as biodefense threats (botulinum neurotoxin, ricin). The company's products are advanced through Phase 1 clinical trials and procured primarily through U.S. government contracts with BARDA and ASPR, with deployment via the Strategic National Stockpile, WHO-coordinated outbreak clinical trials, and expanded access programs.

Product overview

Mapp Biopharmaceutical develops a portfolio of monoclonal antibody therapeutics for infectious diseases, focusing on unmet needs in global health and biodefense. The core products include MBP134 (broad-spectrum anti-filovirus cocktail targeting multiple Ebola species), MBP091 (pan-Marburg therapeutic), ZMapp (Ebola virus treatment), Nipah monoclonal antibody, Botulinum Neurotoxin therapeutic, and earlier-stage candidates for hantavirus, Crimean Congo Hemorrhagic Fever virus, and ricin. The company was founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin and maintains collaborations with BARDA, NIH, and academic partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • MBP134 Investigational monoclonal antibody cocktail targeting multiple ebolaviruses including Zaire, Sudan, Bundibugyo, Reston, Tai Forest, and Bombali species; designed for broad-spectrum treatment of Ebola virus disease.
  • MBP091 Single human monoclonal antibody developed as a pan-Marburg virus therapeutic for treatment of hemorrhagic fevers caused by Marburg and closely related Ravn virus; isolated at Vanderbilt University Medical Center from a Marburg survivor.
  • ZMapp Cocktail of mouse-human chimeric monoclonal antibodies for Ebola virus (Zaire ebolavirus); granted Orphan Medicinal Product Designation by EMA and Fast Track Status by FDA.
  • Nipah Monoclonal Antibody Novel Nipah monoclonal antibody undergoing human clinical trials in India and Bangladesh; designed to offer immediate post-exposure protection against Nipah virus.
  • Botulinum Neurotoxin Therapeutic Next-generation monoclonal antibody-based therapeutic for Botulinum Neurotoxin (BoNT) being developed in partnership with BARDA for biodefense preparedness.
  • Ricin Antibody Monoclonal antibodies providing protection against ricin toxin, including plant-based expression of partially humanized neutralizing antibodies, for biodefense applications.
  • Junin Virus Antibody Humanized monoclonal antibody therapeutic developed for Argentine hemorrhagic fever caused by Junin virus.

Companies that use Mapp Biopharmaceutical

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Mapp Biopharmaceutical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Mapp Biopharmaceutical partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • University of OxfordcoreStrategic or Co-development Partner · 24 June 2026University of Oxford is leading clinical trials of MBP134 and Gilead antivirals in the DRC Ebola outbreak, working with Congolese and Ugandan governments under WHO sponsorship. Oxford is also developing Bundibugyo vaccine candidates in collaboration with the Serum Institute of India.
  • Gilead SciencesminorStrategic or Co-development Partner · 24 June 2026Gilead Sciences is donating doses of remdesivir and obeldesivir for WHO-sponsored clinical trials in DRC, testing Mapp's MBP134 alongside Gilead antivirals to evaluate individual and combination therapy approaches for Bundibugyo ebolavirus.
  • The Alliance for International Medical Action (ALIMA)minorStrategic or Co-development Partner · 24 June 2026ALIMA is partnering with DRC's National Institute for Biomedical Research and Oxford University in WHO-sponsored clinical trials of Mapp and Gilead therapeutics against Bundibugyo ebolavirus.
  • Democratic Republic of Congo National Institute for Biomedical ResearchcoreStrategic or Co-development Partner · 24 June 2026DRC's National Institute for Biomedical Research is collaborating with WHO, Oxford University, and ALIMA to conduct clinical trials of Mapp's MBP134 and Gilead's antivirals against the Bundibugyo ebolavirus outbreak.
  • Vanderbilt University Medical CentercoreStrategic or Co-development Partner · 11 June 2019Dr. James Crowe's laboratory at Vanderbilt isolated the MBP091 monoclonal antibody from a survivor of Marburg virus infection. The antibody was subsequently licensed by Mapp for development as a pan-Marburg therapeutic.
  • Adimab LLCcoreStrategic or Co-development Partner · 28 September 2018Collaboration with Adimab LLC led by Dr. Laura Walker for identification of monoclonal antibodies from survivors of the 2013-2016 Ebola outbreak. Mapp obtained exclusive license to develop and commercialize these antibodies from Adimab and Albert Einstein College of Medicine. The partnership utilized Adimab's antibody discovery platform.
  • Albert Einstein College of MedicinecoreStrategic or Co-development Partner · 28 September 2018Academic partner in the antibody discovery collaboration. Part of NIAID-supported Centers of Excellence for Translational Research at four institutions. Mapp obtained exclusive license to develop and commercialize antibodies from Adimab and Einstein.
  • National Institute of Allergy and Infectious Diseases (NIAID)coreStrategic or Co-development Partner · 28 September 2018NIAID-supported Centers of Excellence for Translational Research at multiple institutions (Albert Einstein College of Medicine, Public Health Agency of Canada, University of Texas Medical Branch at Galveston, and USAMRIID) collaborated on antibody identification. NIAID funding supported research through grants (U19AI109711, U19AI109762, HHSN2722011000221).

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Mapp Biopharmaceutical competitors and assessment

Company assessment

Direct peers

  • Vir Biotechnology: Clinical-stage immunology company developing monoclonal antibody therapeutics for serious infectious diseases, including influenza, hepatitis B, and coronaviruses. Directly comparable to Mapp in antibody platform, infectious disease focus, and pre-commercial clinical development stage.
  • BioCryst Pharmaceuticals: Commercial-stage biotech developing therapeutics for rare infectious diseases and hereditary angioedema. Comparable business model targeting underserved infectious disease indications with government stockpiling and small patient populations.

Broad incumbents

  • Regeneron Pharmaceuticals: Large biotech with a deep monoclonal antibody platform that developed REGN-EB3 (Inmazeb), an approved Ebola therapeutic that directly competes with Mapp's ZMapp/MBP134 in the filovirus treatment market. Comparable antibody technology and government countermeasure positioning.
  • Emergent BioSolutions: Specialty biopharmaceutical company focused on biodefense and public health preparedness products, including vaccines and antibody therapeutics for anthrax, smallpox, and botulinum. Comparable biodefense countermeasure business with strong U.S. government customer base.
  • Gilead Sciences: Large antiviral pharmaceutical company and current Mapp partner donating remdesivir/obeldesivir for combination trials in the Bundibugyo outbreak. Overlapping infectious disease franchise and government countermeasure positioning.
  • Merck & Co. Large pharmaceutical company with a major vaccines and infectious disease franchise, including Ervebo Ebola vaccine and partnerships with government health authorities on outbreak response. Comparable global infectious disease countermeasure footprint.

Emerging players

  • Ridgeback Biotherapeutics: Late-stage biopharmaceutical company developing therapeutics for infectious diseases, including the approved oral antiviral molnupiravir for COVID-19 and Ebola antibody programs. Comparable emerging infectious disease biotech with government-aligned business model.
  • SAB Biotherapeutics: Clinical-stage biopharmaceutical company developing polyclonal antibody therapeutics for infectious diseases and immune disorders. Comparable antibody platform focus and government countermeasure contracts.
  • Leaf Biopharmaceutical: Biopharmaceutical company that in-licensed Mapp's filovirus monoclonal antibody technology in 2014 for commercialization. Closely connected emerging player in the same therapeutic area.
  • CureVac: Clinical-stage biopharmaceutical company developing mRNA-based vaccines and therapeutics for infectious diseases and oncology. Comparable emerging biotech with government countermeasure contracts and infectious disease focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Mapp Biopharmaceutical social profiles

Digital presence

Mapp Biopharmaceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mapp Biopharmaceutical leadership team

Management profile

Number of profiles

Profiles5 records

Mapp Biopharmaceutical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mapp Biopharmaceutical M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mapp Biopharmaceutical

What does Mapp Biopharmaceutical do?

Mapp Biopharmaceutical develops investigational monoclonal antibody therapeutics for the prevention and treatment of infectious diseases, with emphasis on filoviruses (Ebola, Marburg, Bundibugyo), Nipah virus, and other high-consequence pathogens as well as biodefense threats (botulinum neurotoxin, ricin). The company's products are advanced through Phase 1 clinical trials and procured primarily through U.S. government contracts with BARDA and ASPR, with deployment via the Strategic National Stockpile, WHO-coordinated outbreak clinical trials, and expanded access programs.

Is Mapp Biopharmaceutical a public or private company?

Mapp Biopharmaceutical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Mapp Biopharmaceutical founded?

Mapp Biopharmaceutical was founded in 2003. It employs 51 to 100 people.

Where is Mapp Biopharmaceutical based?

Mapp Biopharmaceutical is headquartered in San Diego, United States, in the North America region.

How does Mapp Biopharmaceutical make money?

Two revenue lines are on record. Government Contracts and BARDA Funding is the primary driver. The others are U.S. Government Procurement.

Who are Mapp Biopharmaceutical's main competitors?

Direct peers on record are Vir Biotechnology and BioCryst Pharmaceuticals. Broad incumbents are Regeneron Pharmaceuticals, Emergent BioSolutions, Gilead Sciences and Merck & Co.. Emerging players are Ridgeback Biotherapeutics, SAB Biotherapeutics, Leaf Biopharmaceutical and CureVac.

Does Mapp Biopharmaceutical have an API?

No public API is recorded for Mapp Biopharmaceutical.

What industry is Mapp Biopharmaceutical in?

Mapp Biopharmaceutical's product category is Infectious Disease Therapeutics. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAIAEAF, Pandemic Preparedness & Rapid-Response Vaccines. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AllafricaUganda: U.S. Donates Experimental Antibody Treatment to Bolster Uganda's Fight Against EbolaThe United States government delivered an experimental antibody treatment, MBP134, to Uganda's Ministry of Health, with Dr Charles Ayume receiving it on behalf of the ministry. The treatment, developed by Mapp Biopharmaceutical with BARDA support, is held for immediate use if a new Ebola case is detected, though Uganda has no active cases. The US has committed more than $619 million to regional Ebola response.StuffThis Ebola outbreak has claimed over 2,000 lives. Here's why it is so hard to containAn Ebola outbreak in eastern Congo has claimed over 2,000 lives, caused by the rare Bundibugyo virus, and is occurring in a volatile region where health workers face attacks and community suspicion. Local Ebola responders have gone on strike over unpaid wages, further straining an already overstretched response in an area with limited healthcare access. Researchers have begun a clinical study testing two experimental treatments, Gilead Sciences' remdesivir and Mapp Biopharmaceutical's MBP134, on approximately 1,000 participants.The Denver PostWhy the fastest-growing Ebola outbreak in history is becoming more challengingThe Ebola outbreak in eastern Democratic Republic of Congo has become the fastest-growing in history with 1,031 deaths confirmed, caused by the rare Bundibugyo virus for which there is no approved treatment or vaccine. Health workers at treatment centers have gone on strike over unpaid salaries and bonuses, further straining containment efforts in an already volatile region facing rebel threats, misinformation, and bare-bones infrastructure. Researchers have begun enrolling participants in a clinical study testing two potential treatments: Gilead Sciences' remdesivir and Mapp Biopharmaceutical's experimental MBP134 antibody therapy.San Diego Union-TribuneWhy the fastest-growing Ebola outbreak in history is becoming more challengingThe Ebola outbreak in eastern Congo's Ituri province has killed 1,031 people and is now the fastest-growing in history, caused by the rare Bundibugyo virus with no approved treatment or vaccine. Health workers at Ebola treatment centers have gone on strike over unpaid salaries and bonuses, threatening containment efforts in a volatile region already facing rebel threats, misinformation, and bare-bones infrastructure. Researchers have begun enrolling participants in a clinical study testing two experimental treatments — Gilead Sciences' remdesivir and Mapp Biopharmaceutical's MBP134 — with the WHO warning it could take months and up to 1,000 participants to determine efficacy.The Mercury NewsWhy the fastest-growing Ebola outbreak in history is becoming more challengingThe Ebola outbreak in eastern Democratic Republic of Congo has become the fastest-growing in history, with over 2,000 confirmed cases and more than 750 deaths from the Bundibugyo virus, which has no approved vaccines. Healthcare workers at two treatment centers have gone on strike over unpaid wages, further straining containment efforts in an already volatile region facing rebel threats and community mistrust. A clinical study testing two experimental treatments—Gilead Sciences' remdesivir and Mapp Biopharmaceutical's MBP134—has begun enrolling participants, though officials warn it could take months and up to 1,000 participants to determine efficacy.Winnipeg Free PressWhy the fastest-growing Ebola outbreak in history is becoming more challengingThe Ebola outbreak in eastern Democratic Republic of Congo has become the fastest-growing in history, with 2,473 confirmed cases and 999 deaths as of the latest update, concentrated primarily in Ituri province. The crisis is compounded by strikes by unpaid health workers at treatment centers, amid existing challenges including rebel violence, community mistrust, and the rarity of the Bundibugyo virus strain for which no approved vaccine or treatment exists. Researchers have begun enrolling participants in a clinical study testing two experimental treatments—Gilead Sciences' remdesivir and Mapp Biopharmaceutical's MBP134—though officials warn results could take months and require up to 1,000 participants.MarketScreenerWhat Bundibugyo Ebola vaccines and treatments are under developmentGlobal health authorities are accelerating the development of vaccines, therapies, and diagnostic tests for the Bundibugyo Ebola strain following an outbreak in eastern Democratic Republic of Congo that has caused 2,473 confirmed cases and 999 deaths, with no approved medical countermeasures currently available for this strain. Multiple vaccine candidates are in development, including those from the University of Oxford (manufactured by the Serum Institute of India), the International AIDS Vaccine Initiative, Moderna, and Public Health Vaccines, with the WHO recommending several experimental drugs for priority evaluation. Antibody-based therapies from Mapp Biopharmaceutical and Regeneron Pharmaceuticals, antiviral drugs from Gilead Sciences, and diagnostic tests from companies including Roche, BioFire Defense, Altona Diagnostics, and OraSure Technologies are also being assessed or deployed in the outbreak region.Daily RecordEbola outbreak is fastest-growing on record with more than 2,000 cases and 750 deadThe current Ebola outbreak in the Democratic Republic of Congo has become the fastest in history with over 2,000 cases confirmed and more than 750 deaths, with suspected cases emerging around Kisangani. The World Health Organization reports that 80% of new cases are linked to unknown transmission chains, making containment significantly more difficult, while unpaid health workers have gone on strike at treatment centers further straining response efforts. Clinical trials have begun testing two potential treatments: Gilead Sciences' remdesivir and Mapp Biopharmaceutical's MBP134 experimental therapy.GulfNewsWhy the fastest-growing Ebola outbreak in history is becoming more challengingThe Ebola outbreak in eastern Democratic Republic of Congo has become the fastest-growing in history, with nearly 2,000 confirmed cases including 702 deaths, and suspected cases now spreading to two additional provinces including the city of Kisangani. Healthcare workers at a treatment center in Ituri province went on strike over unpaid salaries, adding to existing challenges of rebel threats, community distrust, and misinformation about the virus. Researchers have begun enrolling participants in a clinical trial testing two potential treatments—Gilead Sciences' remdesivir and Mapp Biopharmaceutical's experimental MBP134—for the Bundibugyo virus strain, which currently has no approved vaccines.Japan TodayWhy the fastest-growing Ebola outbreak in history is becoming more challengingThe Ebola outbreak in eastern Democratic Republic of Congo has become the fastest-growing in history, with nearly 2,000 confirmed cases and 702 deaths as the Bundibugyo virus continues spreading to additional provinces including Kisangani. Healthcare workers at a treatment center in Ituri province went on strike over unpaid salaries, threatening containment efforts in an already crisis-stricken region facing rebel threats, misinformation, and bare-bones infrastructure. Researchers have begun enrolling participants in a clinical study testing two experimental treatments—Gilead Sciences' remdesivir and Mapp Biopharmaceutical's MBP134—though officials warn it could take months and up to 1,000 participants to determine efficacy.